Janssen’s Tecvayli (teclistamab) Receives Health Canada Authorization for Relapsed or Refractory Multiple Myeloma
Shots:
- Health Canada has issued a NOC/c for Tecvayli in adult patients with r/r MM who received 3 prior lines of therapy, incl. a proteasome inhibitor, an immunomodulatory agent & an anti-CD38 mAb
- The authorization was based on the P-I/II study (MajesTEC-1) which showed that patients treated with Tecvayli, a SC administered therapy showed deep and durable responses in a patient population with m-DoR of 14.9mos. among triple-class exposed patients
- ORR (62.4%) with a median follow-up of 14.1mos., VGPR or better (57.6%) and CR (36.8%), the median time to the first confirmed response was 1.2mos., serious adverse reactions (65%), neurologic toxicities in 15% while immune effector cell-associated neurotoxicity syndrome in 3% of patients
Ref: Newswire | Image: Janssen
Related news:- Janssen’s Tecvayli (teclistamab-cqyv) Receives the US FDA’s Approval for the Treatment of Relapsed or Refractory Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
